IP Library Granted Patent US 8,440,721
Granted Patent B2
US 8,440,721 · App. 13/184,704 · Granted May 14, 2013

Methods for concomitant administration of colchicine and a second active agent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,721
App. No.
13/184,704
Granted
May 14, 2013
Kind
B2
Abstract

Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.

Claims (7)

1. A method of treating a patient in need of treatment for acute gout flares with colchicine, comprising

orally administering an adjusted daily dosage amount of colchicine to the patient who is receiving concomitant administration of verapamil,

wherein the adjusted daily dosage amount of colchicine is 50% to 75% of an intended daily dosage amount of colchicine,

wherein the intended daily dosage amount of colchicine is a dosage amount suitable for the patient if the patient were not receiving concomitant verapamil, wherein the intended daily dosage amount of colchicine suitable for the patient if the patient were not receiving concomitant verapamil is 1.2 mg at the first sign of flare, followed by 0.6 mg one hour later, and wherein the concomitantly administered dose of verapamil is 240 mg per day.

2. The method of claim 1 , wherein the dose is not to be repeated for 3 days.

3. The method of claim 1 , wherein the adjusted daily dosage amount of colchicine is 1.2 mg.

4. The method of claim 3 , wherein the dose is not to be repeated for 3 days.

Assignments (3)
CHANGE OF NAME Recorded Nov 30, 2012
From: MUTUAL PHARMACEUTICAL COMPANY, INC.
To: MPC OLDCO, INC.
Reel/Frame 029377/0901 →
MERGER Recorded Nov 30, 2012
From: MPC OLDCO, INC.
To: MPC MERGER SUB, INC.
Reel/Frame 029380/0671 →
MERGER Recorded Nov 30, 2012
From: MPC MERGER SUB, INC.
To: TAKEDA PHARMACEUTICALS U.S.A., INC.
Reel/Frame 029380/0855 →